THEORETICAL EXPLORATION OF YIQI HUAYU JIEDU THERAPY COMBINED WITH TRASTUZUMAB AND CHEMOTHERAPY IN THE TREATMENT OF ENDOMETRIAL CANCER

Abstract

Endometrial cancer is a common female reproductive system malignancy with rising morbidity and mortality annually. Trastuzumab combined with paclitaxel and carboplatin chemotherapy is the standard regimen for HER2 - positive endometrial cancer, exerting anti - tumor effects by blocking HER2 signaling, inhibiting JAK/STAT pathway activation, and downregulating PD - L1 expression. However, it has limitations such as severe adverse events and acquired drug resistance. According to TCM theory, endometrial cancer is related to "beng lou" and "zheng jia", with a core pathogenesis of vital qi deficiency and retention of damp - heat, blood stasis, and toxin in the uterus. Yiqi Huayu Jiedu therapy, a classic TCM anti - tumor regimen, can regulate the tumor microenvironment, reduce inflammatory mediator levels, and reverse drug resistance with few adverse reactions. This review summarizes the mechanisms and limitations of trastuzumab plus chemotherapy, analyzes the synergistic effects of combined TCM and Western medicine treatment, and shows that Yiqi Huayu Jiedu therapy can alleviate treatment - related toxicities and enhance anti - tumor sensitivity. This combined regimen integrates TCM holistic concepts with modern precision medicine, offering a novel strategy for HER2 - positive endometrial cancer, which is of great value for improving patient survival and quality of life.